Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study ; volume:9 ; number:1 ; day:26 ; month:11 ; year:2014 ; pages:1-10 ; date:12.2014
Orphanet journal of rare diseases ; 9, Heft 1 (26.11.2014), 1-10, 12.2014
- Creator
-
Schiffmann, Raphael
- Contributor
-
Pastores, Gregory M.
Lien, Yeong-Hau H.
Castaneda, Victoria
Chang, Peter
Martin, Rick
Wijatyk, Anna
SpringerLink (Online service)
- DOI
-
10.1186/s13023-014-0169-6
- URN
-
urn:nbn:de:1111-2016050124945
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Schiffmann, Raphael
- Pastores, Gregory M.
- Lien, Yeong-Hau H.
- Castaneda, Victoria
- Chang, Peter
- Martin, Rick
- Wijatyk, Anna
- SpringerLink (Online service)
Other Objects (12)
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
Evaluation of the URGOnight Tele-neurofeedback Device: An Open-label Feasibility Study with Follow-up
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
Pegunigalsidase alfa (Morbus Fabry) : Addendum zum Projekt A23-95 (Dossierbewertung)
Pegunigalsidase alfa (Morbus Fabry) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Behandlungswechsel von Agalsidase beta zu Agalsidase alfa bei Morbus Fabry
Pegunigalsidase alfa für die Behandlung des Morbus Fabry : Enzymersatztherapie der neuen Generation
Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open‐label, follow‐up trial
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
Enzymersatztherapie bei Morbus Anderson-Fabry : Einfluss von Agalsidase alfa (Replagal) auf den Energiestoffwechsel
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
Evaluation of the URGOnight Tele-neurofeedback Device: An Open-label Feasibility Study with Follow-up
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
Pegunigalsidase alfa (Morbus Fabry) : Addendum zum Projekt A23-95 (Dossierbewertung)
Pegunigalsidase alfa (Morbus Fabry) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Behandlungswechsel von Agalsidase beta zu Agalsidase alfa bei Morbus Fabry
Pegunigalsidase alfa für die Behandlung des Morbus Fabry : Enzymersatztherapie der neuen Generation
Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open‐label, follow‐up trial
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial
Enzymersatztherapie bei Morbus Anderson-Fabry : Einfluss von Agalsidase alfa (Replagal) auf den Energiestoffwechsel
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
Evaluation of the URGOnight Tele-neurofeedback Device: An Open-label Feasibility Study with Follow-up
Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study
Pegunigalsidase alfa (Morbus Fabry) : Addendum zum Projekt A23-95 (Dossierbewertung)
Pegunigalsidase alfa (Morbus Fabry) : Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung
Behandlungswechsel von Agalsidase beta zu Agalsidase alfa bei Morbus Fabry
Pegunigalsidase alfa für die Behandlung des Morbus Fabry : Enzymersatztherapie der neuen Generation
Long‐term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: an open‐label, follow‐up trial
IGF-1 in autosomal dominant cerebellar ataxia - open-label trial
Effects of practicing yoga on alexisomia: an open-label trial